Board of Directors
Gil Kliman, MD
General Partner, InterWest
Dr. Gil Kliman leads the medical device investment team at InterWest Partners and invests in a broad array of healthcare opportunities, with a special interest in ophthalmology and digital health. He is a board member of Doximity, Glaukos, Gobiquity, Restoration Robotics, and ReVision Optics, and a prior board member of IntraLase and LenSx.
A former practicing ophthalmologist, Gil completed an ophthalmology residency at Wills Eye Institute and retina fellowship at Massachusetts Eye and Ear Infirmary as a Heed Fellow. He has a B.A. from Harvard University, an M.D. from the University of Pennsylvania and an M.B.A. from Stanford University.
General Partner and Co-Head of Global Venture Capital, OrbiMed
Jonathan Silverstein is a General Partner and Co-Head of Global venture capital at OrbiMed, the world’s largest asset management firm solely focused in healthcare with roughly $15 billion in assets under management. OrbiMed manages over a dozen different hedge, venture capital, royalty and mutual funds. OrbiMed has over 110 employees throughout its 5 offices around the globe: New York, San Francisco, Mumbai, Shanghai and Tel Aviv. Four times (from 2012 to 2015) Mr. Silverstein was named to the Forbes Midas List, a list of the world’s top 100 venture capitalists. Mr. Silverstein has a J.D. and an M.B.A. from the University of San Diego, and a B.A. in Economics from Denison University.
Currently, Mr. Silverstein is the Chairman of Intercept (ICPT), Cerapedics, and Audentes and is a board member of, Glaukos (GKOS), DFine, Rhythm, Ascendis (ASND) and Roka Biosciences (ROKA). Mr. Silverstein was formerly a chairman, director or observer of Arteaus (sold to LLY), Enobia (sold to ALXN), SuperDimension (sold to Covidien), Nxstage Medical (NXTM), Insulet Corporation (PODD), LifeCell (sold to KCI), Given Imaging (sold to Covidien),Cerexa (sold to FRX), Peninsula Pharmaceuticals (sold to JNJ), Predix (sold to EPIX), Avanir(AVNR), Orthovita (sold to SYK), Auxillium (sold to ENDO), Bioenvision (sold to GENZ), Adiana(sold to HOLX), Civitas (sold to ACOR), Relypsa (RLYP) and Adolor (sold to CBST).
Joe Mandato, PhD
Managing Director, De Novo Ventures
Joe has held senior positions with several leading medical device and technology firms. He joined De Novo Ventures as managing director in 2003. Joe also is an adjunct faculty member of the University of San Francisco Graduate School of Management and co-professor of the course, Medical Device Innovation, at Stanford University.
Among other responsibilities, he has served as chairman of Confer Software, a developer of software used to create efficiencies and streamline processes in healthcare and as president and CEO of Origin Medsystems, a developer of minimally invasive surgical devices for use in general, cardio-thoracic, and ob-gyn surgery, which was acquired by Eli Lilly & Company in 1992 and spun out as one of the units which formed Guidant Corporation in 1995. At Guidant, Joe was a member of the founding management committee and CEO of two of its five operating units, Origin and Heart Rhythm Technology.
Earlier in his career, he was CEO of Ioptex Research, a developer of intraocular lenses used in cataract surgery, which was acquired by Smith & Nephew PLC. He joined Ioptex from Cilco AG, a unit of Rorer Group, where he served as CEO. He began his career in healthcare as a Captain in the U.S. Army Medical Service Corps.
Robert J. Palmisano
President & CEO, Wright Medical Group, Inc.
Mr. Palmisano joined Wright as President & CEO in September of 2011. He has significant experience leading publicly-traded medical device companies, most recently serving as President & CEO of ev3, Inc., a global endovascular device company, from April 2008 to July 2010, when it was acquired by Covidien plc. Prior to leading ev3, Mr. Palmisano was President & CEO of IntraLase Corp. from 2003 to 2007 and previously President & CEO of MacroChem Corporation from 2001 to 2003. Earlier in his career, he served as President & CEO of Summit Technology Inc. until it was acquired by Alcon Inc. and in various executive positions at Bausch & Lomb Incorporated. Mr. Palmisano currently serves on the Providence College Board of Trustees. During the past five years, Mr. Palmisano previously served on the Board of Directors of Bausch & Lomb, a privately-held company, and ev3, Inc., Osteotech, Inc., and Abbott Medical Options, Inc., all public companies. Mr. Palmisano holds a B.A. degree in Political Science from Providence College.